Compare Vanguard Intermediate Term Corporate Bond ETF (VCIT) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Intermediate Term Corporate Bond ETF vs Zoetis Inc — how do they compare? Vanguard Intermediate Term Corporate Bond ETF trades at $81.17, while Zoetis Inc trades at $74.22 (market cap $30.39B). The key difference: Zoetis Inc pays a 2.88% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none. Which is the better fit depends on your goals.
| VCIT | ZTS | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $84.82 | $156.76 |
52-Week Low | $81.07 | $71.91 |
Market Cap | — | $30.39B |
Enterprise Value | — | $37.95B |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VCIT, the Vanguard Intermediate-Term Corporate Bond ETF, trades at $81.20 with a slight 0.16% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators are neutral. The fund maintains consistent monthly dividend distributions, with recent payouts around $0.33-$0.34. News highlights VCIT's competitive 0.03% expense ratio and approximately 5% yield compared to peers like iShares corporate bond ETFs, emphasizing its cost efficiency for income-focused investors.
The outlook for VCIT is mixed, offering attractive income through corporate bond exposure but facing interest rate sensitivity. Opportunities include high relative yield and low fees, while risks involve corporate credit deterioration and Fed policy shifts. Investors should weigh yield advantages against potential volatility from economic changes.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
